CanSino Biologics (HKG:6185, SHA:688185) narrowed its attributable loss in the first quarter to 11.5 million yuan from 170.1 million yuan in the year-ago period, a Tuesday Hong Kong bourse filing said.
Loss per share stood at 0.05 yuan, down from 0.69 yuan in the same period of the last fiscal year.
The vaccine manufacturer saw its operating revenue for the three months rise by 20% to 137.2 million yuan from 114.3 million yuan a year prior.
The firm attributed the lower loss mainly to an increase in operating revenue amid a rising market share of its vaccine product Menhycia in China, a rise in other income due to government grants and international funding support, and reduced spillover costs.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。